vs
Side-by-side financial comparison of CSP INC (CSPI) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $12.0M, roughly 1.5× CSP INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 0.8%, a 65.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -23.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -6.3%).
CSP Inc. is a U.S.-based technology firm offering cybersecurity solutions, managed IT services, high-performance computing systems, and IT consulting support. It serves enterprises across healthcare, finance, manufacturing, and public sectors in North America and select global markets.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CSPI vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $18.6M |
| Net Profit | $91.0K | $12.3M |
| Gross Margin | 39.3% | — |
| Operating Margin | -0.9% | 56.3% |
| Net Margin | 0.8% | 65.7% |
| Revenue YoY | -23.2% | 1808.5% |
| Net Profit YoY | -80.7% | 376.5% |
| EPS (diluted) | $0.01 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.0M | $18.6M | ||
| Q3 25 | $14.5M | $334.0K | ||
| Q2 25 | $15.4M | $1.4M | ||
| Q1 25 | $13.1M | $257.0K | ||
| Q4 24 | $15.7M | $977.0K | ||
| Q3 24 | $13.0M | $660.0K | ||
| Q2 24 | $13.1M | $736.0K | ||
| Q1 24 | $13.7M | $1.4M |
| Q4 25 | $91.0K | $12.3M | ||
| Q3 25 | $-191.0K | $-8.6M | ||
| Q2 25 | $-264.0K | $-6.9M | ||
| Q1 25 | $-108.0K | $-5.4M | ||
| Q4 24 | $472.0K | — | ||
| Q3 24 | $-1.7M | $-2.8M | ||
| Q2 24 | $-185.0K | $-14.5M | ||
| Q1 24 | $1.6M | $411.0K |
| Q4 25 | 39.3% | — | ||
| Q3 25 | 36.6% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 32.0% | — | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 28.4% | — | ||
| Q2 24 | 35.0% | — | ||
| Q1 24 | 47.3% | — |
| Q4 25 | -0.9% | 56.3% | ||
| Q3 25 | -3.7% | -2516.5% | ||
| Q2 25 | -7.9% | -701.0% | ||
| Q1 25 | -7.6% | -3350.2% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -15.7% | -1563.6% | ||
| Q2 24 | -5.5% | -1255.0% | ||
| Q1 24 | 9.0% | -692.5% |
| Q4 25 | 0.8% | 65.7% | ||
| Q3 25 | -1.3% | -2572.2% | ||
| Q2 25 | -1.7% | -504.8% | ||
| Q1 25 | -0.8% | -2097.7% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | -12.7% | -425.5% | ||
| Q2 24 | -1.4% | -1964.4% | ||
| Q1 24 | 11.6% | 29.9% |
| Q4 25 | $0.01 | $0.25 | ||
| Q3 25 | $-0.02 | $-0.17 | ||
| Q2 25 | $-0.03 | $-0.14 | ||
| Q1 25 | $-0.01 | $-0.11 | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $-0.17 | $-0.06 | ||
| Q2 24 | $-0.02 | $-0.30 | ||
| Q1 24 | $0.16 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8M | $49.4M |
| Total Assets | $69.2M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $40.0M | ||
| Q3 25 | $27.4M | $37.9M | ||
| Q2 25 | $26.3M | $44.8M | ||
| Q1 25 | $29.5M | $40.6M | ||
| Q4 24 | $30.7M | $59.3M | ||
| Q3 24 | $30.6M | $68.8M | ||
| Q2 24 | $28.9M | $73.0M | ||
| Q1 24 | $27.1M | $80.2M |
| Q4 25 | $44.8M | $49.4M | ||
| Q3 25 | $44.6M | $36.4M | ||
| Q2 25 | $47.5M | $44.5M | ||
| Q1 25 | $47.5M | $50.5M | ||
| Q4 24 | $47.5M | $55.1M | ||
| Q3 24 | $47.3M | $58.5M | ||
| Q2 24 | $48.1M | $60.4M | ||
| Q1 24 | $48.2M | $74.1M |
| Q4 25 | $69.2M | $59.0M | ||
| Q3 25 | $71.2M | $51.1M | ||
| Q2 25 | $66.8M | $60.7M | ||
| Q1 25 | $67.1M | $67.9M | ||
| Q4 24 | $67.5M | $90.6M | ||
| Q3 24 | $69.4M | $99.0M | ||
| Q2 24 | $66.8M | $107.8M | ||
| Q1 24 | $64.2M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $18.4M |
| Free Cash FlowOCF − Capex | $-3.0M | — |
| FCF MarginFCF / Revenue | -25.1% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | -32.04× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $18.4M | ||
| Q3 25 | $1.9M | $-8.7M | ||
| Q2 25 | $-3.3M | $-7.5M | ||
| Q1 25 | $1.9M | $-7.5M | ||
| Q4 24 | $1.7M | $-24.0M | ||
| Q3 24 | $-1.5M | $765.0K | ||
| Q2 24 | $2.4M | $-10.9M | ||
| Q1 24 | $1.7M | $-4.0M |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $-3.3M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $-1.5M | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $1.6M | — |
| Q4 25 | -25.1% | — | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | -21.7% | — | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | -11.7% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 11.9% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | -32.04× | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.04× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
